Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India rejects Bayer Nexavar CL appeal

This article was originally published in Scrip

Executive Summary

India's apex court recently dismissed Bayer's plea in the high profile Nexavar (sorafenib tosylate) compulsory licensing litigation, but the case hearing appears yet again to have touched upon the delicate issue of R&D spends along the way.

You may also be interested in...



Bayer-Natco Stivarga Infringement Case Simmers In India

Bayer is battling Natco in another high-profile infringement suit in India, this time pertaining to its anticancer Stivarga (regorafenib). The case has many legs and is to be re-heard by a single judge on the orders of a division bench.

Novartis’ Entresto Faces Challenge From Natco In India

Natco has launched a cut-price version of sacubitril/valsartan (Novartis' Entresto) on the Indian market and is also believed to have opposed the patent for the heart failure therapy.

India Facing ‘Pincer-Like’ Pressure On IP In Europe, Asia Trade Talks

Humanitarian group MSF says India is facing “pincer-like pressure” to relax its strict patent laws in order to conclude free trade deals in Europe and Asia, and is calling on New Delhi to stand firm.

Topics

Related Companies

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel